Status:
ACTIVE_NOT_RECRUITING
Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient
Lead Sponsor:
University Health Network, Toronto
Conditions:
Small Cell Carcinoma, Hypercalcaemic Type
Ovarian Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a study of pembrolizumab as consolidation therapy for a patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
Detailed Description
It is an open-label single patient Clinical Trial to be conducted at Princess Margaret Cancer Centre for a patient with Small Cell Carcinoma of Ovary - Hypercalcemic Type (SCCOHT) who has rare and agg...
Eligibility Criteria
Inclusion
- Patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)
Exclusion
- N/A
Key Trial Info
Start Date :
December 6 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 2 2024
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT05368207
Start Date
December 6 2021
End Date
November 2 2024
Last Update
March 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9